1
|
Gagelmann N, Eikema DJ, Koster L, Netelenbos T, McDonald A, Stoppa AM, Fenk R, Anagnostopoulos A, van Gorkom G, Deconinck E, Bulabois CE, Delforge M, Bunjes D, Arcese W, Reményi P, Itälä-Remes M, Thurner L, Bolaman AZ, Nabil Y, Lund J, Labussière-Wallet H, Hayden PJ, Beksac M, Schönland S, Yakoub-Agha I. Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study. Eur J Haematol 2023. [PMID: 37082839 DOI: 10.1111/ejh.13981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Revised: 04/11/2023] [Accepted: 04/12/2023] [Indexed: 04/22/2023]
Abstract
BACKGROUND No adequate data exist on the impact of multiple myeloma (MM) with extramedullary disease (EMD) after autograft and maintenance therapy. METHODS We identified 808 patients with newly diagnosed MM who received first autograft, of whom 107 had EMD (83 paraskeletal and 24 organ involvement), and who had been reported to the EBMT registry December 2018. Distribution according to type of involvement was similar between the treatment groups (p = .69). For EMD, 46 (40%) received thalidomide, 59 (51%) lenalidomide, and 11 (10%) bortezomib. RESULTS The median follow-up from maintenance start was 44 months. Three-year progression-free survival (PFS) was 52% (48%-57%) for no EMD, 56% (44%-69%) for paraskeletal involvement, and 45% (22%-68%) for organ involvement (p = .146). Early PFS (within first year) appeared to be significantly worse for organ involvement (hazard ratio, 3.40), while no significant influence was found after first year from maintenance start. Three-year overall survival (OS) was 81% (77%-84%), 88% (80%-96%), and 68% (47%-89%; p = .064), respectively. With thalidomide as reference, lenalidomide was significantly associated with better PFS and OS, whereas bortezomib appeared to improve outcome specifically in EMD. CONCLUSION Lenalidomide maintenance is standard of care for MM without EMD, whereas extramedullary organ involvement remains a significant risk factor for worse outcome, especially for early events after maintenance start.
Collapse
Affiliation(s)
- Nico Gagelmann
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Dirk-Jan Eikema
- Department of Statistics, Leiden University Medical Centre, Leiden, The Netherlands
| | | | | | - Andrew McDonald
- Alberts Cellular Therapy, Pretoria East Hospital, Pretoria, South Africa
| | | | - Roland Fenk
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
| | | | - Gwendolyn van Gorkom
- Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Eric Deconinck
- Clinical Hematology, Besançon University Hospital, Besançon, France
| | - Claude-Eric Bulabois
- Service d'Hematologie, CHU Grenoble Alpes-Universite Grenoble Alpes, Grenoble, France
| | | | - Donald Bunjes
- Department of Internal Medicine III, Bone Marrow Transplantation Unit, University Hospital of Ulm, Ulm, Germany
| | - William Arcese
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - Péter Reményi
- St. István and St. László Hospital of Budapest, Budapest, Hungary
| | - Maija Itälä-Remes
- Turku University Hospital, Stem Cell Transplantation Unit, Turku, Finland
| | - Lorenz Thurner
- Department of Oncology, Hematology, Rheumatology and Clinical Immunology, Saarland University Medical Center, Homburg, Germany
| | - Ali Zahit Bolaman
- Internal Medicine, Division of Hematology, Adnan Menderes University, Aydin, Turkey
| | - Yafour Nabil
- Établissement hospitalier et universitaire, Service d'hématologie et de thérapie cellulaire, Université d'Oran 1, Ahmed Ben Bella, faculté de médecine, Oran, Algeria
| | - Johan Lund
- Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska Institute & University Hospital, Stockholm, Sweden
| | | | - Patrick J Hayden
- Department of Haematology, St. James's Hospital, Dublin, Ireland
| | | | - Stefan Schönland
- Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany
| | - Ibrahim Yakoub-Agha
- INSERM U1286, Centre Hospitalier Universitaire de Lille LIRIC, Lille, France
| |
Collapse
|
2
|
Amini SN, Nelson VS, Porcelijn L, Netelenbos T, Zwaginga JJ, de Haas M, Schipperus MR, Kapur R. The interplay between GPIb/IX antibodies, platelet hepatic sequestration, and TPO levels in patients with chronic ITP. Blood Adv 2023; 7:1066-1069. [PMID: 35901281 PMCID: PMC10034565 DOI: 10.1182/bloodadvances.2022007751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Revised: 06/27/2022] [Accepted: 07/13/2022] [Indexed: 11/20/2022] Open
Abstract
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with an incompletely understood pathophysiology but includes platelet-clearance in the spleen and liver via T cells and/or platelet autoantibodies. Strikingly, thrombopoietin (TPO) levels remain low in ITP. Platelet-glycoprotein (GP)Ibα has been described to be required for hepatic TPO generation; however, the role of GPIb antibodies in relation to platelet hepatic sequestration and TPO levels, with consideration of platelet counts, remains to be elucidated. Therefore, we examined 53 patients with chronic and nonsplenectomized ITP for whom we conducted indium-labeled autologous platelet scintigraphy and measured platelet antibodies and TPO levels. Upon stratification toward the severity of thrombocytopenia, no negative association was observed between GPIb/IX antibodies and TPO levels, suggesting that GPIb/IX antibodies do not inhibit or block TPO levels. Surprisingly, we observed a positive association between GPIb/IX antibody levels and TPO levels and GPIb/IX antibodies and platelet hepatic sequestration in patients with severe, but not mild or moderate, thrombocytopenia. In addition, platelet hepatic sequestration and TPO levels were positively associated. This collectively indicates that GPIb/IX antibodies may be associated with increased platelet hepatic sequestration and elevated TPO levels in patients with severe thrombocytopenic ITP; however, further research is warranted to elucidate the pathophysiologic mechanisms.
Collapse
Affiliation(s)
- Sufia N Amini
- Department of Hematology, Hagaziekenhuis, The Hague, The Netherlands
- Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
| | - Vivianne S Nelson
- Department of Hematology, Hagaziekenhuis, The Hague, The Netherlands
| | | | - Tanja Netelenbos
- Department of Hematology, Hagaziekenhuis, The Hague, The Netherlands
| | - Jaap Jan Zwaginga
- Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
| | - Masja de Haas
- Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
- Sanquin Diagnostics, Amsterdam, The Netherlands
- Department of Clinical Transfusion Research, Sanquin Research, Amsterdam, The Netherlands
| | - Martin R Schipperus
- Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands
- Sanquin Transfusion Services, Amsterdam, The Netherlands
| | - Rick Kapur
- Department of Experimental Immunohematology, Landsteiner Laboratory, Amsterdam University Medical Center, Sanquin Research, University of Amsterdam, Amsterdam, The Netherlands
| |
Collapse
|
3
|
Wiersum-Osselton JC, Slomp J, Frederik Falkenburg JH, Geltink T, van Duijnhoven HLP, Netelenbos T, Schipperus MR. Guideline development for prevention of transfusion-associated graft-versus-host disease: reduction of indications for irradiated blood components after prestorage leukodepletion of blood components. Br J Haematol 2021; 195:681-688. [PMID: 34490619 DOI: 10.1111/bjh.17822] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2021] [Revised: 08/23/2021] [Accepted: 08/24/2021] [Indexed: 11/29/2022]
Abstract
Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare, commonly fatal complication of transfusion preventable by irradiation of blood units. The revision of the Dutch transfusion guideline addressed the question whether irradiation is still necessary if blood components are prestorage leukodepleted. We searched for published cases of TA-GVHD following transfusion of prestorage leukodepleted blood and through contacting haemovigilance systems. Six presumed cases were found, dating from 1998 to 2013. Four out of six patients had received one or more non-irradiated units despite recognised indications for irradiated blood components. In the countries providing information, over 50 million prestorage leukodepleted, non-irradiated, non-pathogen-reduced cellular components were transfused in a 10-year period. Potential benefits of lifting indications for irradiation were considered. These include reduced irradiation costs (€ 1.5 million annually in the Netherlands) and less donor exposure for neonates. Findings were presented in an invitational expert meeting. Recommendations linked to human leukocyte antigen similarity between donor and recipient or intra-uterine transfusion were left unchanged. Indications linked to long-lasting deep T-cell suppression were defined with durations of 6 or 12 months after end of treatment (e.g. autologous or allogeneic stem cell transplantation). Need for continued alertness to TA-GVHD and haemovigilance reporting of erroneous non-irradiated transfusions was emphasised.
Collapse
Affiliation(s)
- Johanna C Wiersum-Osselton
- TRIP (Transfusion and Transplantation Reactions in Patients) Hemovigilance and Biovigilance Office, Leiden, The Netherlands
| | | | | | - Tessa Geltink
- Knowledge Institute of Medical Specialists, Utrecht, The Netherlands
| | | | | | - Martin R Schipperus
- Department of Hematology, University Medical Center UMCG, Groningen, The Netherlands
| |
Collapse
|
4
|
Roex MCJ, Wijnands C, Veld SAJ, van Egmond E, Bogers L, Zwaginga JJ, Netelenbos T, von dem Borne PA, Veelken H, Halkes CJM, Falkenburg JHF, Jedema I. Effect of alemtuzumab-based T-cell depletion on graft compositional change in vitro and immune reconstitution early after allogeneic stem cell transplantation. Cytotherapy 2020; 23:46-56. [PMID: 32948458 DOI: 10.1016/j.jcyt.2020.08.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2020] [Revised: 08/05/2020] [Accepted: 08/07/2020] [Indexed: 12/24/2022]
Abstract
BACKGROUND AIMS To reduce the risk of graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (alloSCT), T-cell depletion (TCD) of grafts can be performed by the addition of alemtuzumab (ALT) "to the bag" (in vitro) before transplantation. In this prospective study, the authors analyzed the effect of in vitro incubation with 20 mg ALT on the composition of grafts prior to graft infusion. Furthermore, the authors assessed whether graft composition at the moment of infusion was predictive for T-cell reconstitution and development of GVHD early after TCD alloSCT. METHODS Sixty granulocyte colony-stimulating factor-mobilized stem cell grafts were obtained from ≥9/10 HLA-matched related and unrelated donors. The composition of the grafts was analyzed by flow cytometry before and after in vitro incubation with ALT. T-cell reconstitution and incidence of severe GVHD were monitored until 12 weeks after transplantation. RESULTS In vitro incubation of grafts with 20 mg ALT resulted in an initial median depletion efficiency of T-cell receptor (TCR) α/β T cells of 96.7% (range, 63.5-99.8%), followed by subsequent depletion in vivo. Graft volumes and absolute leukocyte counts of grafts before the addition of ALT were not predictive for the efficiency of TCR α/β T-cell depletion. CD4pos T cells were depleted more efficiently than CD8pos T cells, and naive and regulatory T cells were depleted more efficiently than memory and effector T cells. This differential depletion of T-cell subsets was in line with their reported differential CD52 expression. In vitro depletion efficiencies and absolute numbers of (naive) TCR α/β T cells in the grafts after ALT incubation were not predictive for T-cell reconstitution or development of GVHD post- alloSCT. CONCLUSIONS The addition of ALT to the bag is an easy, fast and generally applicable strategy to prevent GVHD in patients receiving alloSCT after myeloablative or non-myeloablative conditioning because of the efficient differential depletion of donor-derived lymphocytes and T cells.
Collapse
Affiliation(s)
- Marthe C J Roex
- Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
| | - Charissa Wijnands
- Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
| | - Sabrina A J Veld
- Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
| | - Esther van Egmond
- Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
| | - Lisette Bogers
- Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
| | - Jaap J Zwaginga
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands; Center for Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands
| | - Tanja Netelenbos
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands; Department of Hematology, HagaZiekenhuis, The Hague, The Netherlands
| | | | - Hendrik Veelken
- Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
| | | | | | - Inge Jedema
- Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
| |
Collapse
|
5
|
Netelenbos T, Massey E, de Wreede LC, Harding K, Hamblin A, Sekhar M, Li A, Ypma PF, Ball L, Zwaginga JJ, Stanworth SJ. The burden of invasive infections in neutropenic patients: incidence, outcomes, and use of granulocyte transfusions. Transfusion 2018; 59:160-168. [PMID: 30383912 PMCID: PMC7379528 DOI: 10.1111/trf.14994] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2018] [Revised: 08/02/2018] [Accepted: 08/03/2018] [Indexed: 12/20/2022]
Abstract
BACKGROUND Patients with prolonged neutropenia caused by chemotherapy or underlying marrow disorders are at risk of invasive bacterial and fungal infections. New treatment options alongside targeted antimicrobial therapy that might improve outcomes include granulocyte transfusions (GTX). To inform the research agenda, a prospective observational cohort study was performed in the Netherlands and United Kingdom. The aim was to describe the incidence, characteristics, and outcomes of patients developing invasive infections and assess patients fulfilling criteria for GTX. STUDY DESIGN AND METHODS All patients receiving myeloablative chemotherapy and anticipated to develop 7 or more days of neutropenia (<0.5 × 109/L) were eligible and followed for the development of invasive infections according to a defined algorithm and mortality up to 100 days. Secondary outcomes were types of infection and eligibility for GTX. RESULTS A total of 471 patients enrolled at six hematology‐oncology departments were followed for 569 neutropenic episodes. Overall, 32.5% of patients developed invasive infections during their first episode. Significant baseline risk factors for developing infections were high comorbidity scores (WHO performance status ≥ 2, hazard ratio [HR], 2.6 [1.7‐3.9]; and hematopoietic cell transplantation‐comorbidity index score ≥ 2 HR 1.3 [0.9‐1.8]). Infections were bacterial (59.4%) and fungal (22.3%). Despite 34 patients (6.3% of all episodes) appearing to meet criteria to receive GTX, only nine patients received granulocytes. The HR for death was 5.8 (2.5‐13.0) for patients with invasive infections. CONCLUSION This study documents that invasive infections are associated with significant mortality. There is a need for new strategies to prevent and treat infections, which may include better understanding of use GTX. See article on page 6–8, in this issue
Collapse
Affiliation(s)
- Tanja Netelenbos
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands
| | - Edwin Massey
- University Hospitals Bristol NHS Foundation Trust and NHS Blood and Transplant Bristol, Bristol, United Kingdom
| | - Liesbeth C de Wreede
- Medical Statistics Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands
| | - Kay Harding
- University Hospitals Bristol NHS Foundation Trust and NHS Blood and Transplant Bristol, Bristol, United Kingdom
| | - Angela Hamblin
- Oxford University Hospitals NHS Foundation Trust & Oxford BRC Hematology Theme Oxford, Oxford, United Kingdom
| | - Mallika Sekhar
- Department of Hematology, Royal Free Hospital London, London, United Kingdom
| | - Anna Li
- Department of Hematology, Royal Free Hospital London, London, United Kingdom
| | - Paula F Ypma
- Department of Hematology, HAGA Hospital, The Hague, the Netherlands
| | - Lynn Ball
- Department of Pediatrics, Leiden University Medical Center, Leiden, the Netherlands
| | - Jaap Jan Zwaginga
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands.,Center for Clinical Transfusion Research, Sanquin-LUMC, Leiden, the Netherlands
| | - Simon J Stanworth
- Oxford University Hospitals NHS Foundation Trust & Oxford BRC Hematology Theme Oxford, Oxford, United Kingdom
| |
Collapse
|
6
|
Kruizinga MD, van Tol MJ, Bekker V, Netelenbos T, Smiers FJ, Bresters D, Jansen-Hoogendijk AM, van Ostaijen-ten Dam MM, Kollen WJ, Zwaginga JJ, Lankester AC, Bredius RG. Risk Factors, Treatment, and Immune Dysregulation in Autoimmune Cytopenia after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients. Biol Blood Marrow Transplant 2018; 24:772-778. [DOI: 10.1016/j.bbmt.2017.12.782] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2017] [Accepted: 12/09/2017] [Indexed: 10/18/2022]
|
7
|
Morton S, Stanworth S, Lozano M, Harrison S, Hong F, Dennington P, McQuilten Z, Worel N, Compernolle V, Kutner J, Yokoyama A, Nahirniak S, Germain M, Hume H, Robitaille N, Wilson A, Tinmouth A, Massey E, Boulat C, Woimant G, Tiberghien P, Schulze TJ, Bux J, Pierelli L, Ballester C, Netelenbos T, West KA, Conry-Cantilena C, Eder A, Haley NR, Yazer M, Triulzi D. Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use. Vox Sang 2017; 112:e48-e68. [DOI: 10.1111/vox.12523] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- S. Morton
- NHS Blood and Transplant; University Hospitals Birmingham NHS Foundation Trust; Birmingham UK
| | - S. Stanworth
- NHS Blood and Transplant; Oxford University Hospital NHS Foundation Trust; Oxford UK
| | | | - S.J. Harrison
- Peter MacCallum Cancer Centre; Melbourne Vic. Australia
- Victoria Comprehensive Cancer Centre, Grattan Street; Melbourne Vic. 3000 Australia
- Sir Peter MacCallum Department of Oncology; Melbourne University; Melbourne Vic. 3000 Australia
| | - F.S. Hong
- Clinical Services and Research; Australian Red Cross Blood Service; 100 Batman St West Melbourne Vic. 3003 Australia
| | - P. Dennington
- Clinical Services and Research; Australian Red Cross Blood Service; 17 O'Riordan Street Alexandria NSW 2015 Australia
| | - Z. McQuilten
- Department of Epidemiology and Preventive Medicine; Monash University; Level 6, 99 Commercial Road Melbourne Vic. 3001 Australia
| | - N. Worel
- Department of Blood Group Serology and Transfusion Medicine; Medical University Vienna; Waehringer Guertel 18-20 A-1090 Vienna Austria
| | - V. Compernolle
- Belgian Red Cross-Flanders; Blood Services; Ottergemsesteenweg 413 B-9000 Ghent Belgium
| | - J.M. Kutner
- Hospital Israelita Albert Einstein; Av. Albert Einstein, 627 - Banco de Sangue 05651-901 Sao Paulo SP Brazil
| | - A.P.H. Yokoyama
- Hospital Israelita Albert Einstein; Av. Albert Einstein, 627 - Banco de Sangue 05651-901 Sao Paulo SP Brazil
| | - S. Nahirniak
- Department of Laboratory Medicine and Pathology; University of Alberta; 4B1.23 WMC 8440-112 St. Edmonton AB T6G 2B7 Canada
| | - M. Germain
- Medical Affairs; Héma-Québec; 1070 Sciences-de-la-Vie Ave Québec QC G1V 5C3 Canada
| | - H. Hume
- Département de Pédiatrie; Université de Montréal Service d'Hématologie/Oncologie; CHU Sainte-Justine 3175 Côte-Sainte-Catherine Montréal QC H3T 1C5 Canada
| | - N. Robitaille
- Département de Pédiatrie; Université de Montréal Service d'Hématologie/Oncologie; CHU Sainte-Justine 3175 Côte-Sainte-Catherine Montréal QC H3T 1C5 Canada
| | - A. Wilson
- Department of Hematology; McGill University Health Centre; 1001 Boul. Décarie Montréal QC Canada
| | - A. Tinmouth
- Benign Hematology and Transfusion Medicine; Ottawa Hospital and Ottawa Hospital Research Institute; 501 Smyth Rd Box 201a Ottawa ON K1H 8L6 Canada
| | - E. Massey
- Benign Hematology and Transfusion Medicine; Ottawa Hospital and Ottawa Hospital Research Institute; 501 Smyth Rd Box 201a Ottawa ON K1H 8L6 Canada
| | - C. Boulat
- Etablissement Français du Sang; 20 Avenue du Stade de France 93218 La Plaine St Denis Cedex France
| | - G. Woimant
- Etablissement Français du Sang; 20 Avenue du Stade de France 93218 La Plaine St Denis Cedex France
| | - P. Tiberghien
- Etablissement Français du Sang; 20 Avenue du Stade de France 93218 La Plaine St Denis Cedex France
| | - T. J. Schulze
- Institute of Transfusion Medicine and Immunology; Medical Faculty Mannheim; Heidelberg University; German Red Cross Blood Service Baden-Württemberg - Hessen Friedrich-Ebert-Str. 107 68167 Mannheim Germany
| | - J. Bux
- University of Bochum; Linnenkamp 19 Hagen 58093 Germany
| | - L. Pierelli
- Transfusion Medicine and Stem Cells; San Camillo Forlanini Hospital; Circonvallazione Gianicolense 87 00152 Rome Italy
| | - C. Ballester
- Department Hematology and Hemotherapy; Son Espases University Hospital; Carretera de Valldemossa 79 07010 Palma de Mallorca Spain
| | - T. Netelenbos
- Internist-hematologist and transfusion specialist; Department of Immunohematology and Blood Transfusion, E3Q; Leids University Medical Center; Postbus 9600 2300RC Leiden The Netherlands
| | - K. A. West
- Department of Transfusion Medicine; National Institutes of Health Clinical Center; 10 Center Drive Room 1N226 Bethesda MD 20892 USA
| | - C. Conry-Cantilena
- Blood Services Section; NIH/CC/DTM; Building 10 Room 1C711 Bethesda MD 20892 USA
| | - A. Eder
- Blood Services Section; NIH/CC/DTM; Building 10 Room 1C711 Bethesda MD 20892 USA
| | - N. R. Haley
- Bloodworks Northwest; Medical Services; 921 Terry Avenue Seattle WA 98104 USA
| | - M. Yazer
- University of Pittsburgh; Pittsburgh; PA USA
- University of Southern Denmark; Odense Denmark
| | - D. Triulzi
- Division of Transfusion Medicine; Department of Pathology; University of Pittsburgh Pittsburgh PA USA
| |
Collapse
|
8
|
Morton S, Stanworth S, Lozano M, Harrison S, Hong F, Dennington P, McQuilten Z, Worel N, Compernolle V, Kutner J, Yokoyama A, Nahirniak S, Germain M, Hume H, Robitaille N, Wilson A, Tinmouth A, Massey E, Boulat C, Woimant G, Tiberghien P, Schulze T, Bux J, Pierelli L, Ballester C, Netelenbos T, West K, Conry-Cantilena C, Eder A, Haley N, Yazer M, Triulzi D. Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use: summary. Vox Sang 2017; 112:680-683. [DOI: 10.1111/vox.12522] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- S. Morton
- NHS Blood and Transplant; University Hospitals Birmingham NHS Foundation Trust; Vicent Drive Edgbaston Birmingham B15 2SG UK
| | - S. Stanworth
- NHSBT/Oxford University Hospital NHS Foundation Trust; Radcliffe Department of Medicine; John Radcliffe Hospital; University of Oxford; Headington, Oxford OX3 9BQ UK
| | - M. Lozano
- Department of Hemotherapy and Hemostasis; University Clinic Hospital; University of Barcelona; Villarroel 170 08036 Barcelona Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
van Oostrum A, Zwaginga JJ, Croockewit S, Overdevest J, Fechter M, Ruiterkamp B, Brand A, Netelenbos T. Predictors for successful PBSC collection on the fourth day of G-CSF-induced mobilization in allogeneic stem cell donors. J Clin Apher 2017; 32:397-404. [DOI: 10.1002/jca.21528] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2016] [Revised: 10/30/2016] [Accepted: 01/10/2017] [Indexed: 11/11/2022]
Affiliation(s)
- Anja van Oostrum
- Department of Immunohematology and Blood Transfusion; Leiden University Medical Centre; Leiden The Netherlands
| | - Jaap Jan Zwaginga
- Department of Immunohematology and Blood Transfusion; Leiden University Medical Centre; Leiden The Netherlands
- Centre for Clinical Transfusion Research, Sanquin; Leiden The Netherlands
| | - Sandra Croockewit
- Department of Hematology; Radboud University Medical Centre; Nijmegen The Netherlands
| | - Jacqueline Overdevest
- Department of Immunohematology and Blood Transfusion; Leiden University Medical Centre; Leiden The Netherlands
| | | | - Bart Ruiterkamp
- Department of Hematology; Radboud University Medical Centre; Nijmegen The Netherlands
| | | | - Tanja Netelenbos
- Department of Immunohematology and Blood Transfusion; Leiden University Medical Centre; Leiden The Netherlands
| |
Collapse
|
10
|
Bank I, Wiersum-Osselton JC, Van Walraven SM, Netelenbos T, Fechter M, Marijt-van der Kreek T, Bär BMAM, Van der Bom JG, Brand A. Donors' health state the year after peripheral haematopoietic progenitor cell collection: A prospective follow-up study in related and unrelated donors compared to first-time platelet donors. J Clin Apher 2016; 31:523-528. [PMID: 26812941 DOI: 10.1002/jca.21444] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Accepted: 12/09/2015] [Indexed: 11/10/2022]
Abstract
Granulocyte colony-stimulating factor (G-CSF) mobilized peripheral haematopoietic progenitor cells collected by apheresis (HPC-A) are the most common source used for allogeneic hematopoietic stem cell transplantation (HSCT). Retrospective short and long-term donor follow-up studies show very low risks of serious complications and do not report compelling evidence of increased cancer occurrence. Some studies reported a prolonged period of leucopenia without an obvious association with infectious complications. However, beyond the first few weeks after the procedure a relationship between events is elusive. We therefore evaluated medical service utilization by prospectively recruited HPC-A donors and first-time platelet apheresis donors for comparison for 1 year after donation. Data were prospectively collected using questionnaires and by medical record review. A total of 215 HPC-A donors (111 unrelated donors and 104 related donors) and 96 first-time platelet donors consented to participation in the study. Follow-up was available for 202 (96%): questionnaires were returned by 74% and records from nonstudy contacts were available for 94% of donors. During the 1-year follow-up, 94 of the donors who returned questionnaires sought medical attention for diagnostic evaluation and/or treatment: 41% of HPC-A donors and 40% of platelet donors. Medical service utilization the first year after HPC-A donation is similar to that after first-time platelet donation. The occurrence of serious medical conditions in both related and unrelated HPC-A donors underscores the importance of participation in long-term follow-up in large cohorts. The findings in this relatively small cohort contribute to evidence on the safety of G-CSF mobilization and HPC-A. J. Clin. Apheresis 31:523-528, 2016. © 2015 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- I Bank
- Sanquin - LUMC Jon J. Van Rood Centre for Clinical Transfusion Research, Leiden, the Netherlands.,Center for Innovation in Medical Education, Leiden University Medical Center, Leiden, the Netherlands
| | - J C Wiersum-Osselton
- Donor Services Unit, Sanquin Blood Supply, Leiden, the Netherlands.,TRIP Hemovigilance and Biovigilance Office, Leiden, the Netherlands
| | - S M Van Walraven
- TRIP Hemovigilance and Biovigilance Office, Leiden, the Netherlands.,Europdonor Foundation, Leiden, the Netherlands
| | - T Netelenbos
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, the Netherlands
| | - M Fechter
- Europdonor Foundation, Leiden, the Netherlands
| | | | - B M A M Bär
- Stem Cell Donor Bank Europdonor Nijmegen, Nijmegen, the Netherlands
| | - J G Van der Bom
- Sanquin - LUMC Jon J. Van Rood Centre for Clinical Transfusion Research, Leiden, the Netherlands
| | - A Brand
- Sanquin - LUMC Jon J. Van Rood Centre for Clinical Transfusion Research, Leiden, the Netherlands.,Europdonor Foundation, Leiden, the Netherlands
| |
Collapse
|
11
|
van Halteren AGS, Dierselhuis MP, Netelenbos T, Fechter M. Donor parity no longer a barrier for female-to-male hematopoietic stem cell transplantation. Chimerism 2015; 5:56-8. [PMID: 24933732 DOI: 10.4161/chim.29562] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is a widely applied treatment for disorders mainly involving the hematopoietic system. The success of this treatment depends on many different patient- and donor-specific factors. Based on higher CD34+ yields and superior clinical outcomes associated with the use of male donors, males are generally seen as the preferred HSCT donor. In addition, female donors are notorious for bearing memory type lymphocytes induced by previous pregnancies; such alloimmune cells may provoke unwanted immune reactions such as graft-vs.-host disease in transplant recipients. Consequently, many transplant centers try to avoid parous donors, particularly when searching the best unrelated donor for a male patient. We recently showed that parous women with female offspring have an anti-male directed tolerogenic immune status comparable to that of nulliparous donors. As discussed in this article addendum, the sex of the donor's offspring combined with the presence of HY-specific T regulator cells are possibly better selection criteria than parity status per se.
Collapse
Affiliation(s)
- Astrid G S van Halteren
- Immunology Laboratory; Willem Alexander Children's Hospital/Leiden University Medical Center; Leiden, the Netherlands
| | - Miranda P Dierselhuis
- Department of Pediatrics; Willem Alexander Children's Hospital/Leiden University Medical Center; Leiden, the Netherlands
| | - Tanja Netelenbos
- Department of Immunohematology & Blood Transfusion/Leiden University Medical Center; Leiden, the Netherlands
| | | |
Collapse
|
12
|
Worel N, Buser A, Greinix HT, Hägglund H, Navarro W, Pulsipher MA, Nicoloso de Faveri G, Bengtsson M, Billen A, Espino G, Fechter M, Giudice V, Hölig K, Kanamori H, Kodera Y, Leitner G, Netelenbos T, Niederwieser D, van Walraven SM, Rocha V, Torosian T, Vergueiro C, Weisdorf D, Yabe H, Halter JP. Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues. Biol Blood Marrow Transplant 2015; 21:2052-2060. [PMID: 26271194 DOI: 10.1016/j.bbmt.2015.08.009] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2015] [Accepted: 08/05/2015] [Indexed: 12/20/2022]
Abstract
The number of allogeneic hematopoietic stem cell (HSC) transplants performed globally each year continues to increase. Advances in HLA typing, better supportive care, and administration of reduced-intensity conditioning regimens allow treatment of older patients with older sibling donors. Pretransplant donor assessment and testing are very important processes affecting the quality and safety of donation. For unrelated HSC donors detailed recommendations for health assessment have been published, allowing donation only if they are unrestrictedly healthy. Eligibility criteria for related donors are less strict and vary significantly between centers. In situations where a family donor does not meet the suitability criteria for unrelated donors, involved physicians often struggle with the decision whether the matched relative is suitable for donation or not. On behalf of the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues, we intended to develop a consensus document with recommendations for donor workup and final clearance of family donors who would not be able to serve as unrelated donors because of their age or pre-existing diseases. This article covers different topics intending to support decision-making, with the goal of minimizing medical risk to the donor and protection of the recipient from transmissible diseases.
Collapse
Affiliation(s)
- Nina Worel
- Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria.
| | - Andreas Buser
- Blood Transfusion Centre, Swiss Red Cross, Basel, Switzerland; Department of Hematology, University Hospital Basel, Basel, Switzerland
| | | | - Hans Hägglund
- Division of Hematology, Department of Medical Sciences Uppsala University, Uppsala, Sweden
| | | | - Michael A Pulsipher
- Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute/University of Utah, Primary Children's Hospital, Salt Lake City, Utah
| | | | - Mats Bengtsson
- Tobias Registry of Swedish Bone Marrow Donors and Uppsala University, Department of Immunology, Genetics and Pathology, Uppsala, Sweden
| | | | - German Espino
- Department of Internal Medicine, Hematology and Bone Marrow Transplantation Section, University Hospital Caja del Seguro Social, Panama City, Panama
| | - Mirjam Fechter
- Europdonor Foundation Leiden, Leiden University Medical Centre, Leiden, The Netherlands
| | - Valeria Giudice
- Department of Immunohematology and Transfusion Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - Kristina Hölig
- Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Heiwa Kanamori
- Department of Hematology, Kanagawa Cancer Center, Kanagawa, Japan
| | - Yoshihisa Kodera
- Asia-Pacific Blood and Marrow Transplantation Group and Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan
| | - Gerda Leitner
- Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria
| | - Tanja Netelenbos
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
| | | | - Suzanna M van Walraven
- Europdonor Foundation Leiden, Leiden University Medical Centre, Leiden, The Netherlands; Ethics Working Group of the World Marrow Donor Association, Leiden, The Netherlands
| | - Vanderson Rocha
- Oxford University Hospitals NHS Trust, British Bone Marrow Donor Registry and Cord Blood Banks, NHS-BT, Oxford, United Kingdom
| | | | - Carmen Vergueiro
- FCM Santa Casa de São Paulo, Disciplina de Hematologia e Oncologia, São Paulo, Brasil
| | - Daniel Weisdorf
- Bone Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota
| | - Hiromasa Yabe
- Department of Cell Transplantation and Regenerative Medicine, Tokai University School of Medicine, Tokyo, Japan
| | - Jörg P Halter
- Department of Hematology, University Hospital Basel, Basel, Switzerland
| |
Collapse
|
13
|
Bilgin YM, Visser O, Beckers EAM, te Boome LCJ, Huisman C, Ypma PF, Croockewit AJ, Netelenbos T, Kramer EPA, de Greef GE. Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor. Transfusion 2014; 55:1021-7. [PMID: 25641128 DOI: 10.1111/trf.12979] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2014] [Revised: 10/07/2014] [Accepted: 10/10/2014] [Indexed: 12/14/2022]
Abstract
BACKGROUND Plerixafor in combination with granulocyte-colony-stimulating factor (G-CSF) is approved for the use of stem cell collection in patients who fail to mobilize on G-CSF. In 2009 the Stem Cell Working Party of the Dutch-Belgian Cooperative Trial group for Hematology Oncology (HOVON) composed a guideline for the use of plerixafor. According to this guideline it is recommended to add plerixafor to G-CSF in patients with circulating CD34+ cell counts of fewer than 20 × 10(6) /L on 2 consecutive days accompanied by increasing white blood cells. STUDY DESIGN AND METHODS In this analysis we evaluated retrospectively the outcome of the use of this guideline in the Netherlands. In total 111 patients received plerixafor with a median one administration (range, one to four administrations). Of these patients 55.8% had non-Hodgkin lymphoma, 31.5% multiple myeloma, 8.1% Hodgkin lymphoma, and 4.5% nonhematologic malignancies. RESULTS In 63.9% patients sufficient numbers of CD34+ cells were collected. In patients with multiple myeloma more successful mobilizations with plerixafor were observed compared to patients with non-Hodgkin lymphoma (71.4% vs. 61.3%). In patients with circulating CD34+ cell counts of at least 2.0 × 10(6) /L before administration of plerixafor a successful mobilization was achieved in 76.5%, and in the patients with very low (0-1 × 10(6) /L) circulating CD34+ cell counts the success rate was 44.2%. CONCLUSION Application of the HOVON guideline on the just-in-time administration of plerixafor is effective for mobilization of hematopoietic stem cells in the majority of patients. Stem cell yield in patients with non-Hodgkin lymphoma was lower compared to patients with multiple myeloma. Also patients with very low circulating CD34+ cells before addition of plerixafor might benefit from this approach.
Collapse
Affiliation(s)
- Yavuz M Bilgin
- Department of Hematology, Erasmus MC, Rotterdam, the Netherlands
| | - Otto Visser
- Department of Hematology, VUMC, Amsterdam, the Netherlands
| | | | | | | | - Paula F Ypma
- Department of Hematology, HagaZiekenhuis, the Hague, the Netherlands
| | | | - Tanja Netelenbos
- Department of Immunohematology and Blood Transfusion, LUMC, Leiden, the Netherlands
| | - Ellen P A Kramer
- Department of Clinical Chemistry, Isala, Zwolle, the Netherlands
| | | |
Collapse
|
14
|
Netelenbos T, Bouwsma H, Noort FA, de Groot I, de Fijter JW, Zwaginga JJ. Immune adsorption of anti-A/B antibodies prior to ABO-mismatched kidney transplantation: the Leiden experience. Transfus Apher Sci 2013; 48:185. [PMID: 23809827 DOI: 10.1016/j.transci.2013.02.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- T Netelenbos
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
| | | | | | | | | | | |
Collapse
|
15
|
|
16
|
Netelenbos T, Nooij MA, Nortier JWR. Diabetes insipidus and adrenal insufficiency in a patient with metastatic breast cancer. Neth J Med 2006; 64:310-3. [PMID: 16990696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
A patient previously treated for bilateral breast cancer with mastectomy, radiation therapy and in remission on hormonal therapy for more than five years presented with abdominal symptoms from breast cancer relapse. She developed inappropriate polyuria and hypernatraemia, which responded to desmopressin. In combination with the absence of a high signal from the posterior lobe of the pituitary on MRI , these data indicated the presence of partial central diabetes insipidus. The anterior pituitary showed partial failure (low follicle-stimulating hormone, luteinising hormone and insulin-like growth factor-1 levels). Furthermore, primary adrenal insufficiency had developed, ascribed to bilateral tumour invasion of the adrenals. This rare combination of endocrinological failures in a patient with metastatic breast cancer is discussed.
Collapse
Affiliation(s)
- T Netelenbos
- Department of Internal Medicine, Leiden University Medical Centre, Leiden, the Netherlands.
| | | | | |
Collapse
|
17
|
Zweegman S, Van Den Born J, Mus AMC, Kessler FL, Janssen JJWM, Netelenbos T, Huijgens PC, Dräger AM. Bone marrow stromal proteoglycans regulate megakaryocytic differentiation of human progenitor cells. Exp Cell Res 2004; 299:383-92. [PMID: 15350537 DOI: 10.1016/j.yexcr.2004.06.018] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2004] [Revised: 06/06/2004] [Indexed: 11/27/2022]
Abstract
Adherence of hematopoietic progenitor cells (HPCs) to stroma is an important regulatory step in megakaryocytic differentiation. However, the mechanisms through which megakaryocytic progenitors are inhibited by stroma are poorly understood. We examined the role of sulfated glycoconjugates, such as proteoglycans (PGs), on human bone marrow stroma (hBMS). To this end, PG structure was altered by desulfation or enzymatic cleavage. PGs participated in adhesion of human HPC, as desulfation resulted in about 50% decline in adhesion to hBMS. Heparan sulfate proteoglycans (HSPGs) were found to be responsible by showing about 25% decline in adhesion after pre-incubation of HPC with heparin and about 15% decline in adhesion after enzymatic removal of HSPGs from hBMS. Furthermore, PGs were involved in binding cytokines. Both desulfation and enzymatic removal of stromal HSPGs increased release of megakaryocytopoiesis-inhibiting cytokines, that is, interleukin-8 (IL-8, 1.9-fold increase) and macrophage inflammatory protein-1alpha (MIP-1alpha, 1.4-fold increase). The megakaryocytic output of HPC grown in conditioned medium of desulfated stroma was decreased to 50% of the megakaryocytic output in CM of sulfated stroma. From these studies, it can be concluded that PGs in bone marrow, in particular HSPGs, are involved in binding HPC and megakaryocytopoiesis-inhibiting cytokines. Bone marrow stromal PGs thus reduce differentiation of HPC toward megakaryocytes.
Collapse
Affiliation(s)
- Sonja Zweegman
- Department of Hematology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Netelenbos T, van den Born J, Kessler FL, Zweegman S, Huijgens PC, Drager AM. In vitro model for hematopoietic progenitor cell homing reveals endothelial heparan sulfate proteoglycans as direct adhesive ligands. J Leukoc Biol 2003; 74:1035-44. [PMID: 14525970 DOI: 10.1189/jlb.1202593] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Proteoglycans (PGs) play a dominant role within the bone marrow (BM), but their role in homing of transplanted hematopoietic progenitor cells (HPC) is unknown. In this study, the role of heparan sulfate (HS) PGs on BM endothelium as adhesive structures was investigated. HPC (primary CD34+ cells and cell line KG-1a) were able to bind fractionated heparin, which could be competed by highly sulfated heparin/HS-glycosaminoglycans (GAGs). Under flow conditions, HPC adhered to immobilized heparin after rolling over E-selectin. Rolling of KG-1a on BM endothelial cell (EC) line 4LHBMEC was completely E selectin-dependent. Addition of heparin/HS-GAGs, endothelial treatment with chlorate, or anti-HS all partially inhibited firm adhesion. Moreover, enzymatic removal of endothelial HS-GAGs reduced initial adhesion. Finally, HPC-bound PGs isolated from 4LHBMEC, which was largely inhibited by enzymatic HS-degradation. In summary, we identified sulfated structures on BM endothelium, most likely HSPGs, as a novel class of glycoconjugates involved in the multistep homing cascade of HPC.
Collapse
Affiliation(s)
- Tanja Netelenbos
- Department of Hematology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
| | | | | | | | | | | |
Collapse
|
19
|
Netelenbos T, van den Born J, Kessler FL, Zweegman S, Merle PA, van Oostveen JW, Zwaginga JJ, Huijgens PC, Dräger AM. Proteoglycans on bone marrow endothelial cells bind and present SDF-1 towards hematopoietic progenitor cells. Leukemia 2003; 17:175-84. [PMID: 12529676 DOI: 10.1038/sj.leu.2402738] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2001] [Accepted: 07/01/2002] [Indexed: 11/09/2022]
Abstract
Recognition events between hematopoietic progenitor cells (HPC) and bone marrow endothelial cells (BMEC) initiate homing of HPC to the bone marrow. The chemokine SDF-1 is present on BMEC and plays a crucial role in bone marrow engraftment. We studied the role of proteoglycans (PGs) on BMEC in binding and presentation of SDF-1. SDF-1 mRNA was present in three human BMEC cell lines. Competition experiments showed that 125I-SDF-1 alpha binding to the BMEC cell line 4LHBMEC was inhibited by heparins, heparan sulfate (HS) intestinal mucosa, chondroitin and dermatan sulfate (CS/DS), but not by HS bovine kidney. Pretreatment of 4LHBMEC with glycosaminoglycan (GAG)-degrading enzymes or sodium chlorate demonstrated that SDF-1 bound to both HSPGs and CS/DSPGs in a sulfation-dependent manner, as determined with an SDF-1 antibody recognizing the CXCR4-binding site. 4LHBMEC bound four-fold more SDF-1 than HUVEC. Isolated endothelial PGs did not bind SDF-1 in a filter or microplate-binding assay, suggesting the necessity of membrane association. In flow adhesion experiments, endothelial arrest of CXCR4+ KG-1 and not of CXCR4- KG-1a cells increased significantly when SDF-1 was presented on 4LHBMEC. In conclusion, SDF-1 is produced by BMEC and binds to the BMEC cell surface via HS and CS/DS-GAGs, thereby presenting its CXCR4 binding site to HPC contributing to their arrest.
Collapse
Affiliation(s)
- T Netelenbos
- Department of Hematology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
de Boer F, Dräger AM, Pinedo HM, Kessler FL, Monnee-van Muijen M, Weijers G, Westra G, van der Wall E, Netelenbos T, Oberink JW, Huijgens PC, Schuurhuis GJ. Early apoptosis largely accounts for functional impairment of CD34+ cells in frozen-thawed stem cell grafts. J Hematother Stem Cell Res 2002; 11:951-63. [PMID: 12590710 DOI: 10.1089/152581602321080619] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Quality assessment of stem cell grafts is usually performed by flow cytometric CD34(+) enumeration or assessment of clonogenic output of fresh material. Previously, we identified the occurrence of early apoptosis, not detectable with the permeability marker 7-amino actinomycin D (7-AAD), in purified frozen-thawed CD34(+) cells, using the vital stain Syto16. Syto(high)/7-AAD(-) cells were defined as viable, Syto16(low)/7-AAD(-) cells as early apoptotic and Syto16(low)/7-AAD(+) as dead. This was confirmed in a subsequent study using frozen-thawed transplants of lymphoma patients. In the present study on grafts from multiple myeloma and lymphoma patients, we investigated the functional consequences of the early apoptotic process. The mean Syto16-defined viability was 41 and 42%, respectively, for both graft groups, compared to 78% and 72%, respectively, using 7-AAD only. The established early apoptosis marker annexin V missed roughly 50% of the early apoptosis detected with Syto16. In contrast, viability of CD34(+) cells in nonmanipulated whole blood transplants from a matched group of lymphoma patients, after 72 h of storage at 4 degrees C, was more than 90%, even with the Syto16 assay. CFU recovery (median 26-33%) after cryopreservation matched CD34(+) recovery after Syto16, but not 7-AAD correction. In contrast, colony-forming unit (CFU) recovery in the whole blood transplant was close to 100%. Furthermore, early apoptotic CD34(+) cells had lost migratory ability toward stromal cell derived factor-1alpha (SDF-1alpha). The establishment of a Syto16(high)/7-AAD(-) proportion of CD34(+) cells offers a new approach for a more correct determination of the number of viable nonapoptotic CD34(+) cells in stem cell grafts. Further development of this assay should allow its incorporation into the routine CD34(+) assessment of post-thawed samples in clinical flow cytometry laboratories.
Collapse
Affiliation(s)
- Fransien de Boer
- Department of Hematology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Netelenbos T, Zuijderduijn S, van den Born J, Kessler FL, Zweegman S, Huijgens PC, Dräger AM. Proteoglycans guide SDF‐1‐induced migration of hematopoietic progenitor cells. J Leukoc Biol 2002. [DOI: 10.1189/jlb.72.2.353] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Affiliation(s)
- Tanja Netelenbos
- Department of Hematology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands and
| | - Suzanne Zuijderduijn
- Department of Hematology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands and
| | - Jacob van den Born
- Department of Molecular Cell Biology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
| | - Floortje L. Kessler
- Department of Hematology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands and
| | - Sonja Zweegman
- Department of Hematology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands and
| | - Peter C. Huijgens
- Department of Hematology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands and
| | - Angelika M. Dräger
- Department of Hematology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands and
| |
Collapse
|
22
|
Netelenbos T, Zuijderduijn S, Van Den Born J, Kessler FL, Zweegman S, Huijgens PC, Dräger AM. Proteoglycans guide SDF-1-induced migration of hematopoietic progenitor cells. J Leukoc Biol 2002; 72:353-62. [PMID: 12149427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/26/2023] Open
Abstract
Stromal cell-derived factor-1 (SDF-1) is a chemoattractant involved in hematopoietic progenitor cell (HPC) trafficking to the bone marrow. We studied the role of bone marrow endothelial proteoglycans (PGs) in SDF-1-mediated migration of HPC using a transwell assay. A subclone of progenitor cell line KG-1 (KG-1v) was used, displaying CXCR4-dependent transmigration. Cell surface PGs on bone marrow endothelial cell line 4LHBMEC did not mediate SDF-1-induced transendothelial migration. In contrast, transwell filters precoated with various glycosaminoglycans (GAGs) enhanced migration toward SDF-1. SDF-1-induced migration was reduced by degradation of heparan sulfate in subendothelial matrix produced by 4LHBMEC. The stimulating effect of GAGs was caused by the formation of a stable haptotactic SDF-1 gradient, as SDF-1 bound to immobilized GAGs and triggered migration. Soluble heparan sulfate enhanced SDF-1-induced migration dose-dependently, suggesting that SDF-1-heparan sulfate complexes optimized SDF-1 presentation. In conclusion, we provide evidence that PGs in the subendothelial matrix establish an SDF-1 gradient guiding migrating HPC into the bone marrow.
Collapse
Affiliation(s)
- Tanja Netelenbos
- Department of Hematology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
23
|
de Boer F, Kessler FL, Netelenbos T, Zweegman S, Huijgens PC, van der Wall E, van der Linden JAM, Pinedo HM, Schuurhuis GJ, Dräger AM. Homing and clonogenic outgrowth of CD34(+) peripheral blood stem cells: a role for L-selectin? Exp Hematol 2002; 30:590-7. [PMID: 12063026 DOI: 10.1016/s0301-472x(02)00797-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
OBJECTIVE After transplantation of hematopoietic stem cells, adhesion molecules play a major role in the multistep process of engraftment in which L-selectin is suggested to be of relevance. A positive correlation previously was found between the number of reinfused L-selectin(+) stem cells and platelet recovery. In the present study, we determined the role of L-selectin in different engraftment steps, i.e., adhesion to endothelial cells, migration, and clonogenic outgrowth by in vitro assays that closely mimic the in vivo situation. MATERIALS AND METHODS Flow adhesion and migration experiments were performed using the human bone marrow endothelial cell line 4LHBMEC and isolated peripheral CD34(+) cells with or without blocking of L-selectin-ligand interaction. Various clonogenic assays, including serum-free colony-forming unit-megakaryocytes (CFU-MK) and burst-forming unit-megakaryocytes (BFU-MK), were performed with sorted L-selectin(+)L-selectin(-) cells or in the presence of antibodies. RESULTS Blocking of L-selectin on CD34(+) cells did not significantly affect rolling over and firm adhesion to 4LHBMEC. In addition, no role for L-selectin was found in transendothelial migration experiments. Finally, in clonogenic outgrowth of sorted or anti-L-selectin monoclonal antibody-incubated CD34(+) cells, no key role for L-selectin expression could be defined in BFU-MK and CFU-MK assays. CONCLUSION Using in vitro assays for CD34(+) stem cell adhesion, migration, and clonogenic capacity, we were not able to define a major role for L-selectin.
Collapse
Affiliation(s)
- Fransien de Boer
- Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Netelenbos T, Dräger AM, van het Hof B, Kessler FL, Delouis C, Huijgens PC, van den Born J, van Dijk W. Differences in sulfation patterns of heparan sulfate derived from human bone marrow and umbilical vein endothelial cells. Exp Hematol 2001; 29:884-93. [PMID: 11438211 DOI: 10.1016/s0301-472x(01)00653-1] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
OBJECTIVE Heparan sulfates (HS), the polysaccharide side chains of HS proteoglycans, differ in structure and composition of sulfated domains among various tissue types, resulting in selective protein binding. HS proteoglycans on bone marrow endothelial cells (BMEC) could contribute to tissue specificity of the bone marrow endothelium and play a role in the presentation of chemokines such as stromal cell-derived factor-1 (SDF-1) and adhesion of hematopoietic progenitor cells after stem cell transplantations. We characterized differences in HS structure and SDF-1 binding between BMEC and human umbilical vein endothelial cells (HUVEC). MATERIALS AND METHODS Expression of HS proteoglycans on human bone marrow microvessels was investigated by immunohistochemical staining. Comparison of three human BMEC cell lines with HUVEC and an HUVEC cell line was studied by flow cytometry using antibodies against different epitopes of the HS polysaccharide chain. HS proteoglycans were biochemically characterized after isolation from metabolically labeled cultures of the BMEC cell line 4LHBMEC and HUVEC. Binding of radiolabeled SDF-1 to 4LHBMEC and HUVEC and competition with heparins were investigated. RESULTS Bone marrow microvessels constitutively expressed HS proteoglycans. Flow cytometric experiments showed differences in HS chain composition between BMEC and HUVEC. Biochemical characterization revealed more O-sulfation of the N-sulfated domains present in cell-associated HS glycosaminoglycans in 4LHBMEC compared to HUVEC. Binding experiments showed that 4LHBMEC bound more 125[I]-SDF-1 per cell than HUVEC. This could be inhibited largely by heparin and O-sulfated heparin and to a lesser extent by N-sulfated heparin. CONCLUSIONS Cellular HS from BMEC differs in composition from HUVEC. We postulate that the presence of highly sulfated domains in the HS chains from BMEC contributes to tissue specificity of bone marrow endothelium in which HS may be involved in SDF-1 presentation and adhesion of hematopoietic progenitor cells.
Collapse
Affiliation(s)
- T Netelenbos
- Department of Hematology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|